Meeting
2020 ASCO Virtual Scientific Program
SPRING: A Worldwide Innovative Network (WIN) Consortium phase I study of triple therapy (avelumab, axitinib, and palbociclib) in advanced non-small cell lung cancer (NSCLC) with genomic and transcriptomic correlates.
Authors
Benjamin Maurice Solomon
Avera Cancer Institute, Sioux Falls, SD
Benjamin Maurice Solomon , Ana Callejo , Jair Bar , Guy J. Berchem , Lyudmila Bazhenova , Pierre Saintigny , Eric Raymond , Nicolas Girard , Raed Sulaiman , Bruce Prouse , Catherine Bresson , Fanny Wunder , J. Jack Lee , Jacques Raynaud , Eitan Rubin , Vladimir Lazar , Enriqueta Felip , Amir Onn , Brian Leyland-Jones , Razelle Kurzrock
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT03386929
Citation
J Clin Oncol 38: 2020 (suppl; abstr 9581)
DOI
10.1200/JCO.2020.38.15_suppl.9581
Abstract #
9581
Poster Bd #
347
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
eVOLVE-Lung02: A phase 3 study of first-line (1L) volrustomig plus chemotherapy (CT) versus pembrolizumab plus CT in metastatic non-small-cell lung cancer (mNSCLC) with PD-L1 tumor cell (TC) expression <50%.
First Author: Melissa Lynne Johnson
Poster
2023 ASCO Annual Meeting
Real-world outcomes of first-line immune checkpoint inhibitors with or without chemotherapy in KRAS G12C altered NSCLC according to PD-L1 status.
First Author: Charu Aggarwal
Poster
2023 ASCO Annual Meeting
ARC-10: A phase 3 study to evaluate zimberelimab + domvanalimab versus pembrolizumab in front-line, PD-L1-high, locally advanced or metastatic non–small-cell lung cancer.
First Author: Christos Chouaid
Poster
2023 ASCO Annual Meeting
Clinical outcomes among patients with advanced non-small cell lung cancer who received targeted therapy in a real-world setting.
First Author: Mo Yang